Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Summary

The purpose of this study is to confirm the safety and efficacy of Apatinib as the Second-line Therapy in Malignant Melanoma.

Timeline

Start

2017-11-29

Primary completion

2018-11

Completion

2019-11

Publications

• Yuan S, Fu Q, Zhao L, Fu X, Li T, Han L, Qin P, Ren Y, Huo M, Li Z, Lu C, Yuan L, Gao Q, Wang Z. Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. Oncologist. 2022 Jun 8;27(6):e463-e470. doi: 10.1093/oncolo/oyab068.

Drugs

Indications